ImmunityBio, Inc.
IBRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001326110
In the last 90 days, ImmunityBio, Inc. insiders filed 0 open-market purchases and 3 sales; 405 institutions reported holding it in 13F filings for Q2 2026, worth $1.76B in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in ImmunityBio, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 194
- +30 vs. Q1 2024
- Shares held
- 61.9M
- −2.90M (−4.5%) vs. Q1 2024
- Total value
- $391.1M
- +$42.9M (+12.3%) vs. Q1 2024
- New holders
- 51
- 63 more added
- Sold out
- 21
- 46 more reduced
2 institutions that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IBRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 405 | $1.76B |
| Q1 2026 | 386 | $1.36B |
| Q4 2025 | 278 | $338.3M |
| Q3 2025 | 264 | $352.1M |
| Q2 2025 | 242 | $327.9M |
| Q1 2025 | 211 | $239.4M |
| Q4 2024 | 202 | $211.8M |
| Q3 2024 | 182 | $255.6M |
| Q2 2024 | 194 | $391.1M |
| Q1 2024 | 166 | $356.9M |
| Q4 2023 | 148 | $288.9M |
| Q3 2023 | 132 | $84.1M |
| Q2 2023 | 118 | $108.7M |
| Q1 2023 | 147 | $84.1M |
| Q4 2022 | 140 | $256.0M |
| Q3 2022 | 126 | $196.3M |
| Q2 2022 | 132 | $123.1M |
| Q1 2022 | 149 | $199.8M |
| Q4 2021 | 141 | $209.7M |
| Q3 2021 | 121 | $310.9M |
| Q2 2021 | 118 | $390.1M |
| Q1 2021 | 116 | $378.9M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding ImmunityBio, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Panagora Asset Management Inc | 0 | $0 | 0.00% | −27,279−100.0% | Sold out |
| GTS Securities LLC | 0 | $0 | 0.00% | −20,467−100.0% | Sold out |
| Brookstone Capital Management | 0 | $0 | 0.00% | −18,715−100.0% | Sold out |
| Axxcess Wealth Management, LLC | 0 | $0 | 0.00% | −15,800−100.0% | Sold out |
| SEI Investments Co | 0 | $0 | 0.00% | −13,772−100.0% | Sold out |
| Wolverine Trading, LLC | 0 | $0 | 0.00% | −13,303−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −11,285−100.0% | Sold out |
| HighTower Advisors, LLC | 0 | $0 | 0.00% | −10,302−100.0% | Sold out |
| Eqis Capital Management, Inc. | 0 | $0 | 0.00% | −10,023−100.0% | Sold out |
| Metropolitan Life Insurance Co | 0 | $0 | 0.00% | −6,038−100.0% | Sold out |
| Quent Capital, LLC | 0 | $0 | 0.00% | −1,824−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −198−100.0% | Sold out |
| Sofos Investments, Inc. | 0 | $0 | 0.00% | −52−100.0% | Sold out |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 0 | $0 | 0.00% | −26−100.0% | Sold out |
| Investors Research Corp | 0 | $0 | 0.00% | −15−100.0% | Sold out |
| Credit Suisse AG | – | – | – | – | Not filed |
| Winning Points Advisors, LLC | – | – | – | – | Not filed |